亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Adaptation of the Immune Related Response Criteria: Irrecist

医学 适应(眼睛) 免疫系统 免疫学 神经科学 生物
作者
Oliver Bohnsack,Axel Hoos,Katarina Ludajic
出处
期刊:Annals of Oncology [Elsevier]
卷期号:25: iv369-iv369 被引量:60
标识
DOI:10.1093/annonc/mdu342.23
摘要

ABSTRACT Aim: The immune related response criteria were published in November 2009, based on results and clinical findings of the ipilimumab® program. RECIST as published in 2000 had its shortcomings for targeted immunotherapy in oncology and still has with its successor version RECIST 1.1. Investigators may declare progressive disease (PD) too early, when the treatment effect is not yet fully evident. With this paper we introduce irRECIST to further clarify and reduce assessment criteria ambiguity and minimize discordance between sites and independently read results. Methods: The adaptations from RECIST 1.1 and/or irRC, as applicable in an immunotherapy clinical study, are documented in the irRECIST Modifications and Clarifications column in a comparative table format within the charter for Blinded Independent Central Review (BICR). However, typically these independent review details and specifications are not available for investigators at sites. The modifications we introduce represent adaptations of the published criteria based on current radiology practice and clinical trial experience and with that aim to provide more objective and reproducible response assessments for investigators and also central independent image review. Results: Bearing industry demands and RECIST shortcomings in mind we introduce a modification of the irRC to better address patients' treatment, investigators' patient management and sponsors' analysis needs for targeted immunotherapy developments in oncology with irRECIST, based on adaptation of unidimensional measurements aligned with RECIST 1.1. irRECIST will reduce site:central discordance in patient assessment and contains guidance for ambiguous cases and also describes how to evaluate patients with non-measurable non target disease only. Conclusions: RECIST published in 2000 and its successor version RECIST 1.1 from 2009 has its shortcomings for targeted immunotherapy in oncology. With these adapted irRECIST criteria we introduce the needed adjustment to the irRC criteria to allow for treatment evaluations and assessments that better meets both investigators' and patients' needs and with that better reflects sponsors' demands for more reliable and reproducible study data analyses. Disclosure: All authors have declared no conflicts of interest.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
24秒前
wangayting给wangayting的求助进行了留言
1分钟前
赘婿应助鲸落采纳,获得10
1分钟前
1分钟前
鲸落发布了新的文献求助10
1分钟前
1分钟前
上善若水呦完成签到 ,获得积分10
1分钟前
青禾完成签到 ,获得积分10
1分钟前
1分钟前
白云朵儿发布了新的文献求助10
1分钟前
momo发布了新的文献求助10
1分钟前
秋雪瑶应助鲸落采纳,获得10
2分钟前
2分钟前
2分钟前
香妃发布了新的文献求助10
2分钟前
鲸落发布了新的文献求助10
2分钟前
上官若男应助sinyipyeung采纳,获得10
2分钟前
2分钟前
龚幻梦发布了新的文献求助10
2分钟前
情怀应助龚幻梦采纳,获得10
2分钟前
2分钟前
sinyipyeung发布了新的文献求助10
2分钟前
清爽的大树完成签到,获得积分10
2分钟前
3分钟前
高po完成签到 ,获得积分10
3分钟前
3分钟前
龚幻梦发布了新的文献求助10
3分钟前
褚青筠完成签到,获得积分10
3分钟前
秋雪瑶应助龚幻梦采纳,获得10
3分钟前
小球发布了新的文献求助30
3分钟前
3分钟前
4分钟前
龚幻梦发布了新的文献求助10
4分钟前
nenoaowu应助科研通管家采纳,获得20
4分钟前
4分钟前
白云朵儿发布了新的文献求助10
4分钟前
4分钟前
sinyipyeung发布了新的文献求助10
4分钟前
在水一方应助落伍少年采纳,获得10
5分钟前
威武吴完成签到,获得积分10
5分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
行動データの計算論モデリング 強化学習モデルを例として 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2545477
求助须知:如何正确求助?哪些是违规求助? 2175634
关于积分的说明 5600159
捐赠科研通 1896337
什么是DOI,文献DOI怎么找? 946226
版权声明 565355
科研通“疑难数据库(出版商)”最低求助积分说明 503552